ANI Pharmaceuticals Inc. (NASDAQ:ANIP)’s share price rose 3.2% during trading on Tuesday . The company traded as high as $65.91 and last traded at $65.76, with a volume of 143,127 shares. The stock had previously closed at $63.75.

A number of equities research analysts recently weighed in on the stock. TheStreet upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, August 26th. Standpoint Research lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, May 24th. Guggenheim reiterated a “buy” rating and set a $65.00 price objective (up previously from $55.00) on shares of ANI Pharmaceuticals in a report on Friday, June 17th. Raymond James Financial Inc. assumed coverage on shares of ANI Pharmaceuticals in a report on Wednesday, June 22nd. They set a “strong-buy” rating and a $68.00 price objective for the company. Finally, Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $67.00 price objective for the company in a report on Wednesday, July 20th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and three have issued a strong buy rating to the company. ANI Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $64.00.

The firm has a market capitalization of $746.57 million, a price-to-earnings ratio of 76.19 and a beta of 2.84. The company’s 50 day moving average is $64.53 and its 200-day moving average is $51.85.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/ani-pharmaceuticals-inc-anip-stock-price-up-3-2.html

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Thursday, August 4th. The specialty pharmaceutical company reported $1.11 EPS for the quarter, beating the Zacks’ consensus estimate of $0.77 by $0.34. The business earned $31.30 million during the quarter, compared to analysts’ expectations of $27.63 million. ANI Pharmaceuticals had a net margin of 11.02% and a return on equity of 20.12%. The company’s quarterly revenue was up 60.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.55 earnings per share. Equities research analysts expect that ANI Pharmaceuticals Inc. will post $4.12 earnings per share for the current year.

In related news, insider Arthur Przybyl sold 37,455 shares of the company’s stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $66.97, for a total value of $2,508,361.35. Following the completion of the sale, the insider now owns 200,788 shares of the company’s stock, valued at $13,446,772.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Robert W. Schrepfer sold 12,500 shares of the company’s stock in a transaction dated Monday, August 8th. The shares were sold at an average price of $67.06, for a total transaction of $838,250.00. Following the completion of the sale, the vice president now directly owns 17,362 shares of the company’s stock, valued at approximately $1,164,295.72. The disclosure for this sale can be found here. 31.60% of the stock is currently owned by insiders.

Large investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA raised its stake in shares of ANI Pharmaceuticals by 94.9% in the second quarter. BNP Paribas Arbitrage SA now owns 2,364 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 1,151 shares in the last quarter. Bank of Montreal Can purchased a new stake in shares of ANI Pharmaceuticals during the second quarter worth about $177,000. Thrivent Financial for Lutherans purchased a new stake in shares of ANI Pharmaceuticals during the second quarter worth about $204,000. Arizona State Retirement System purchased a new stake in shares of ANI Pharmaceuticals during the second quarter worth about $219,000. Finally, BlackRock Advisors LLC raised its stake in shares of ANI Pharmaceuticals by 6.1% in the second quarter. BlackRock Advisors LLC now owns 3,975 shares of the specialty pharmaceutical company’s stock worth $222,000 after buying an additional 230 shares in the last quarter. 48.74% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations.

5 Day Chart for NASDAQ:ANIP

Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.